Isryl-M 2 Forte Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride (2 mg) and Metformin (1000 mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The sustained-release formulation of Isryl-M 2 Forte Tablet PR facilitates a gradual release of Metformin, promoting better gastrointestinal tolerability and consistent plasma drug levels. This combination is particularly beneficial for patients inadequately controlled on monotherapy or lifestyle modifications alone. It aids in reducing fasting and postprandial blood glucose levels, contributing to overall glycemic stability. The use of Isryl-M 2 Forte Tablet PR should be accompanied by regular monitoring of blood glucose, renal function, and liver enzymes to mitigate potential adverse effects such as hypoglycemia, lactic acidosis, or gastrointestinal disturbances. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to either component. Isryl-M 2 Forte Tablet PR should be prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular medical evaluation.